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Abstract
The antinociceptive effects of honokiol and magnolol, two major bioactive constituents of the bark
of Magnolia officinalis, were investigated on animal paw licking responses and thermal hyperalgesia
induced by glutamate receptor agonists including glutamate, N-methyl-D-aspartate (NMDA), and
metabotropic glutamate 5 receptor (mGluR5) activator (RS)-2-chloro-5-hydroxyphenylglycine
(CHPG), as well as inflammatory mediators such as substance P and prostaglandin E2 (PGE2) in
mice. The actions of honokiol and magnolol on glutamate-induced c-Fos expression in the spinal
cord dorsal horn were also examined. Our data showed that honokiol and magnolol blocked
glutamate-, substance P- and PGE2-induced inflammatory pain with similar potency and efficacy.
Consistently, honokiol and magnolol significantly decreased glutamate-induced c-Fos protein
expression in superficial (I-II) laminae of the L4-L5 lumbar dorsal horn. However, honokiol was
more selective than magnolol for inhibition of NMDA-induced licking behavioral and thermal
hyperalgesia. In contrast, magnolol was more potent to block CHPG-mediated thermal
hyperalgesia. These results demonstrate that honokiol and magnolol effectively decreased the
inflammatory pain. Furthermore, their different potency on inhibition of nociception provoked by
NMDA receptor and mGluR5 activation should be considered.
Background
In inflammatory pain, the neurotransmitters (glutamate
and serotonin), neuromodulators (substance P) and
inflammatory mediators (bradykinin, histamine and
prostaglandin) released from the primary afferents and
dorsal horn neurons under tissue damage play an impor-
tant role in eliciting the hyperactivity on nociceptive
behaviors [1-5]. A number of evidence has further sup-
ported the development of central hyperexcitability and
persistent pain relating to the activation of N-methyl-D-
aspartate (NMDA) receptors [6]. The glutamatergic system
is well known to involve in the inflammatory hyperalge-
sia, since NMDA and non-NMDA receptor antagonists
attenuate the nociceptive behaviors which are associated
with inflammatory responses in various animal models
[7]. Recently, we have observed that honokiol and mag-
nolol, isolated from the bark of Magnolia officinals [8,9],
possess the ability to block the glutamate receptor-medi-
ated intracellular cation signals [10] and inhibit gluta-
mate-induced cell damage [11]. According to the above
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evidence, it is proposed that honokiol and magnolol may
have the potent analgesic activity via blockade of gluta-
mate receptors.
Magnolol has been reported to inhibit acetic acid-induced
nociceptive response, and to reduce the hind-paw edema
induced by carrageenan, compound 48/80, and poly-
myxin B in mice [12]. Our previous study also demon-
strates that honokiol and magnolol block the
inflammatory phase of the overt nociception induced by
formalin. However, they do not produce analgesia in tail-
flick, hot-plate paw-licking and the neurogenic phase of
formalin-induced licking response [13]. Thus, we suggest
that honokiol and magnolol may not affect the thermal
pain, but reduce the inflammatory pain. Therefore, the
antinociceptive mechanisms of honokiol and magnolol
particularly in inflammatory pain require further investi-
gation.
In the present study, we evaluated the antinociceptive
actions of honokiol and magnolol on pain behaviors
induced by glutamate receptor agonists including gluta-
mate, NMDA, and mGluR5 agonist (RS)-2-chloro-5-
hydroxyphenylglycine (CHPG), and inflammatory medi-
ators such as substance P and prostaglandin E2 (PGE2),
and also characterized their effects on glutamate-induced
c-Fos expression in the spinal cord. Our results showed
that honokiol and magnolol produced antinociceptive
effects against glutamate-, NMDA-, CHPG-, substance P-
and PGE2-induced inflammatory pain. Honokiol was
more selective for inhibition of NMDA-induced licking
behavioral and thermal hyperalgesia. Alternatively, mag-
nolol was more potentially to block CHPG-mediated ther-
mal hyperalgesia. Furthermore, honokiol and magolol
also significantly decreased c-Fos expression induced by
glutamate in the spinal cord.
Materials and methods
Animals
Male NMRI mice (8-9 weeks, 33-39 g) were supplied from
the Laboratory Animal Center of Tzu Chi University
(Hualien, Taiwan) and housed 4-5 animals per cage in a
12 hr light/dark cycle with free access to food and water.
The experimental protocol was approved by Review Com-
mittee of the Tzu Chi University for the use of animal.
Glutamate-induced nociceptive test
Investigation of excitatory amino acid (EAA), glutamate,
involving in nociception has been described previously
[14]. Briefly, a volume of 20 μl of glutamate (300 μg) was
intraplantarly (i.pl.) injected into the ventral surface of
the hind paw. Animals were observed individually for 30
min following glutamate injection. The amount of time
spent licking the injected paw was recorded with a chro-
nometer and was considered as indicative of nociception.
For examining the antinociceptive effects, honokiol and
magnolol (5 and 10 mg/kg, i.p.) were applied to animals
20 min before glutamate injection (i.pl.). Control animals
received a similar volume of vehicle (corn oil, 10 ml/kg).
NMDA- and PGE2-induced nociceptive test
NMDA (150 μg) or PGE2 (0.5  μg) were intraplantarly
(i.pl.) injected into the ventral surface of the hind paw.
Animals were observed individually for 5 min following
NMDA or PGE2 injection. The amount of time spent lick-
ing the injected paw was recorded with a chronometer
and was considered as indicative of nociception. Animals
were pretreated with vehicle, honokiol and magnolol (0.1
to 1.0 μg/paw, i.pl.) 15 min before NMDA or PGE2 injec-
tion.
Measurement of thermal hyperalgesia
Thermal hypersensitivity was determined by animal hind
paw withdrawal response in hot water (47.0 ± 0.1°C). In
order to calm down the animal's anxiety, each mouse was
wrapped in a sock before any testing. Then the hind paw
was immersed into a water bath (47.0 ± 0.1°C) to meas-
ure the hind paw withdrawal latency. The initial paw-
withdrawal latency (T0) was measured before any nocice-
ptive chemical treatment and the cut-off time was limited
to 10 sec in order to minimize tissue damage. The nocice-
ptive chemicals such as glutamate, NMDA, CHPG, PGE2
or substance P were given as an intraplantar injection into
one hind paw, which was then immersed into hot water
for the observation of paw withdrawal latency (T1) at 5,
15, 30, 60 and 120 min after chemical injection. For a
measurement of antinociceptive properties, honokiol and
magnolol were intraperitoneally (5 or 10 mg/kg) injected
20 min before glutamate injection, or intraplantarly (0.05
to 1.0 μg/paw) treated 15 min before NMDA, CHPG,
PGE2 or substance P injection. Control animals received
an injection of an appropriate volume of vehicle. Data
were expressed as a mean value of Δ paw-withdrawal
latency which was calculated as T0 - T1.
c-Fos immunohistochemistry
Mice were pretreated with vehicle (corn oil), honokiol or
magnolol (10 mg/kg, i.p.) 20 minutes before injection of
saline or glutamate into the plantar surface. Ninety min-
utes after injection of saline or glutamate, mice were
deeply anaesthetized with thiopental (50 mg/kg, i.p.),
then perfused transcardially with heparin solution (1000
USP/ml in 0.1 M PBS), and subsequently perfused with
100 ml of cold fixative (4% paraformaldehyde in 0.1 M
PBS). The L4-L5 segments of spinal cord were removed,
postfixed, and cryoprotected with 30% sucrose in 0.1 M
PBS. Spinal cord tissues were then frozen and cut with a
cryostat in frontal sections (50 μm thickness) which were
collected in 0.1 M PBS for immunohistochemistry as
described previously [15]. Rabbit primary antibody (Ab)Journal of Biomedical Science 2009, 16:94 http://www.jbiomedsci.com/content/16/1/94
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for c-Fos (Santa Cruz, 1:5000) was used to identify the
number of c-Fos labeled neurons of laminas I-II in ran-
domly selected sections (4-5 sections per mouse).
c-Fos immunoreactivity was observed in the cell nuclei
and shown as a brownish round dot in the spinal cord sec-
tions under a light microscope. Quantification of Fos pos-
itive nuclei were counted with the aid of a Nikon Eclipse
800 microscope, equipped with a Polaroid DMC digital
camera (1600 × 1200 dpi in 8 bits) with 100× magnifica-
tion using the Image Pro Plus 4.5 morphometry program
(Media Cybernetics, Silver, MD). Following background
subtraction, the threshold was adjusted so that pale- and
deep-stained nuclei could be equally recognized by the
counting program. Cell counts were made with the help of
the Image Pro Plus 4.5 software and manually counted by
an observer who was blind to the group assignment. The
number of c-Fos-stained nuclei was counted in four sec-
tions per animal in superficial dorsal horn (laminae I and
II) of the L4-L5 lumbar dorsal horn ipsilateral to the for-
malin-injected site.
Materials
Honokiol and magnolol were purchased from Nacalai
Tesque (Kyoto, Japan) and dissolved in corn oil as a stock
solution. c-Fos antibody was purchased from Santa Cruz
Biotechnology (Delaware Avenue, CA, USA). CHPG,
metabotropic glutamate 5 receptor (mGluR5) agonist,
was purchased from Tocris (Northpoint Fourth Way
Avonmouth, UK). Other chemicals were obtained from
Sigma (St. Louis, MO, USA).
Data analysis
Most data are expressed as means ± S.E.M. Statistical sig-
nificance of difference between groups was determined by
two way repeated measures ANOVA, two-way ANOVA or
one-way ANOVA followed by a Student-Newman-Keuls
post-hoc test. A P value of less than 0.05 was considered
statistically significant.
Results
Effects of honokiol and magnolol on nociceptive responses 
and thermal hyperalgesia induced by glutamate receptor 
agonists
To test whether the antinociceptive actions of honokiol
and magnolol are involved in glutamatergic regulation,
we assessed the effects of honokiol and magnolol on
glutamate and NMDA induced licking response and ther-
mal hyperalgesia in mice. As shown in Figure 1, honokiol
and magnolol applied by intraperitoneal injection (i.p.)
at 10 mg/kg significantly inhibited the glutamate-induced
cumulative licking time and thermal hyperalgesia. Moreo-
ver, intraplantar application (i.pl.) of honokiol and mag-
nolol (0.1-1.0 μg/paw) also concentration-dependently
reduced the total licking time and thermal hyperalgesia
induced by NMDA [(F(3,144) = 27.17, P < 0.001) and
F(3,136) = 3.875, P = 0.017, respectively] (Fig. 2). How-
ever, magnolol at lower dose (0.1 μg/paw) did not signif-
icantly alter NMDA-induced nociceptive responses and
thermal hyperalgesia (Fig. 2B and 2D).
The following study was undertaken to investigate
whether the analgesia elicited by honokiol and magnolol
is associated with the inhibition of metabotropic gluta-
mate receptor (mGluR) activity. CHPG (1 μg/paw), a
selective mGlu5 receptor agonist, was observed to induce
a significant increase in the latency of thermal hyperalge-
sia. However, the thermal hyperalgesic effects of CHPG
were inhibited by honokiol (0.1-1 μg/paw) and magnolol
(0.05-0.5 μg/paw). Importantly, magnolol at lower does
(0.05  μg/paw) could reduce CHPG-induced thermal
hyperalgisia (Fig. 3).
Effects of honokiol and magnolol on inflammatory 
mediator-induced nociceptive responses and thermal 
hyperalgesia
The intraplantar injection of substance P (0.5 μg/paw)
and PGE2 (0.5 μg/paw) significantly decreased the paw
withdrawal latency, which was gradually disappeared 2 h
after injection (Fig. 4 and Fig. 5C, 5D). The thermal hyper-
algesia induced by substance P was dose-dependently
inhibited by honokiol (0.5-1.0 μg/paw, i.pl.) and mag-
nolol (0.5-1.0 μg/paw, i.pl.) [F(2, 109) = 9.04, P = 0.002
and F(2, 92) = 42.5, P < 0.001, respectively] (Fig. 4).
Furthermore, honokiol (0.5-1.0 μg/paw, i.pl.) and mag-
nolol (0.5-1.0 μg/paw, i.pl.) inhibited the nociceptive
behaviors and thermal hyperalgesia [F(2, 84) = 1.182, P <
0.001 and F(2, 84) = 19.6, P < 0.001, respectively]
induced by intraplantar injection of PGE2 (Fig. 5).
Effect of honokiol and magnolol on glutamate-induced c-
Fos expression
The highest counts of c-Fos-positive cells were observed at
superficial (I-II) laminae of the L4-L5 lumbar dorsal horn
ipsilateral to the glutamate-injected site (Fig. 6B). In con-
trast, there were little or no c-Fos-positive cells in the con-
tralateral spinal cord of glutamate injection or ipsilateral
of saline-injected site (Fig. 6A). Honokiol (10 mg/kg) and
magnolol (10 mg/kg) significantly decreased the gluta-
mate-induced c-Fos protein expression in superficial spi-
nal cord dorsal horn (Fig. 6).
Discussion
Our previous report has indicated that honokiol and mag-
nolol possess the ability to inhibit formalin-induced
inflammatory nociception [13]. The present results fur-
ther demonstrated that honokiol and magnolol attenu-
ated glutamate-, NMDA-, mGluR5 agonist CHPG-,
substance P- and PGE2-induced nociceptive responses.Journal of Biomedical Science 2009, 16:94 http://www.jbiomedsci.com/content/16/1/94
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The inhibitory actions of honokiol on NMDA-induced
licking behavioral and thermal hyperalgesia were more
potent than magnolol. In contrast, magnolol had higher
potency than honokiol to block CHPG-mediated thermal
hyperalgesia. Importantly, both honokiol and magnolol
significantly decreased glutamate-induced c-Fos protein
expression in superficial (I-II) laminae of the L4-L5 lum-
bar dorsal horn. Taken together, these results indicated
that the analgesic actions of honokiol and magnolol may
be related to the blockade of glutamate receptor, NMDA
receptor and mGlu5 receptor activation, and inflamma-
tion-mediated nociception.
Accumulating evidence has demonstrated that the excita-
tory amino acid glutamate and the glutamatergic recep-
tors, both ionotropic and metabotropic glutamate
receptors (iGluR and mGluRs), are critically contributed
to nociceptive neurotransmission under the development
and maintenance of pain responsiveness [16-19]. In
response to noxious stimuli or tissue injury, excitatory
amino acids are released in peripheral neurons or spinal
cord [20,21]. Then activation of glutamate receptors, espe-
cially NMDA receptors, is involved in the development of
spinal hyperexicitability and persistent pain transmission
[6]. Consistently, NMDA receptor antagonists are
reported to inhibit the spread of pain sensation and the
hyperexcitability of spinal cord nociceptive neurons
induced by C-fiber stimulation [22,23]. Furthermore,
modulation of mGluRs can regulate peripheral nociceptor
function. Importantly, activation of mGluR5 is contrib-
Effects of honokiol and magnolol on glutamate-induced nociceptive responses and thermal hyperalgesia in mice Figure 1
Effects of honokiol and magnolol on glutamate-induced nociceptive responses and thermal hyperalgesia in 
mice. Honokiol (5 and 10 mg/kg), magnolol (5 and 10 mg/kg) and vehicle (corn oil) were intraperitoneally administered 20 min 
prior to glutamate (300 μg) injection into hindpaw, and the total time spent licking the hindpaw was measured for 30 min after 
intraplantar injection of glutamate (A, B). The paw withdrawal latency in hot water at 47°C was measured during 5-120 min 
after intraplantar injection of glutamate (C, D). Each point represents the mean ± S.E.M. (n = 6-8). * indicates significantly dif-
ferent from vehicle group, *p < 0.05.
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uted to the maintenance of peripheral nociceptive proc-
esses which are associated with inflammatory pain but
not in physiological pain [24]. Peripheral injection of
mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyrid-
ine (MPEP), inhibits the inflammatory, but not the neu-
rogenic phase of nociception induced by formalin [25].
However, activation of group III mGluRs, mGluR4 and
mGluR7, just evokes the antinociceptive action on neuro-
pathic pain [26]. In this regard, the inhibitory effects of
honokiol and magonol on inflammatory pain mediated
by mGluR5 activation were examined in this study. Here
our results demonstrated that honokiol and magnolol
reduced glutamate-, NMDA- and CHPG (mGluR5 ago-
nist)-induced licking behavioral and thermal hyperalge-
sia, suggesting that the antinociceptive actions of
honokiol and magnolol may be related to the inhibition
of glutamate receptors including both NMDA and mGlu5
receptors.
It has been demonstrated that noxious stimuli-induced
release of glutamate from nociceptive afferents in spinal
cord, leading to the activation of either iGluR or mGluR
on the postsynapse [21]. Fos, a nuclear phosphoprotein
induced by a mammalian c-Fos protooncogene, is
regarded as a maker of spinal activated neurons after nox-
ious stimulation, such as thermal, mechanical and chem-
ical stimuli [27]. Because c-Fos protein also contributes to
behavioral hyperalgesia, the c-Fos expression in spinal
cord after glutamate stimulation and the influences of
honokiol and magnolol on glutamate-induced c-Fos
Effects of honokiol and magnolol on NMDA-induced nociceptive responses and thermal hyperalgesia in mice Figure 2
Effects of honokiol and magnolol on NMDA-induced nociceptive responses and thermal hyperalgesia in mice. 
Honokiol (0.1-1.0 μg/paw), magnolol (0.1-1.0 μg/paw) and vehicle were intraplantarly administered 20 min prior to NMDA 
(150 μg) injection into hindpaw, and the total time spent licking the hindpaw was measured for 5 min after intraplantar injec-
tion of NMDA (A, B). The paw withdrawal latency in hot water at 47°C was measured during 5-120 min after intraplantar 
injection of NMDA (C, D). Each point represents the mean ± S.E.M. (n = 8-16). * indicates significantly different from vehicle 
group, *p < 0.05.
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Effects of honokiol and magnolol on CHPG-induced thermal hyperalgesia in mice Figure 3
Effects of honokiol and magnolol on CHPG-induced thermal hyperalgesia in mice. Honokiol (0.1-1.0 μg/paw), mag-
nolol (0.05-0.5 μg/paw) and vehicle were administered 20 min prior to CHPG (1 μg) injection into hindpaw. The paw with-
drawal latency in the 47°C water was measured during 5-120 min after intraplantar injection of CHPG. Each point represents 
the mean ± S.E.M. (n = 7-19). * indicates significantly different from vehicle group, *p < 0.05.
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Effects of honokiol and magnolol on substance P-induced thermal hyperalgesia in mice Figure 4
Effects of honokiol and magnolol on substance P-induced thermal hyperalgesia in mice. Honokiol (0.5 or 1.0 μg/
paw), magnolol (0.5 or 1.0 μg/paw) and vehicle were administered 20 min prior to substance-P (0.5 μg) injection into hindpaw. 
The paw withdrawal latency in the 47°C water was measured during 5-120 min after intraplantar injection of substance P. Each 
point represents the mean ± S.E.M. (n = 7-9). * indicates significantly different from vehicle group, *p < 0.05.
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expression were determined in this study. Here our data
showed that honokiol and magnolol attenuated gluta-
mate-induced c-Fos protein expression in superficial lam-
inae of dorsal horn of the spinal cord. This inhibition on
c-Fos expression was correlated to reduction in glutamate-
induced nociceptive response and thermal hyperalgesia.
The present finding is also in agreement with the inhibi-
tory actions of NMDA and mGlu5 receptor antagonists on
c-Fos expression in spinal neurons after noxious stimula-
tion [28,29]. It is important to note that the antinocicep-
tive potency of honokiol is higher than magnolol on
NMDA-induced nociception, although their antinocicep-
tive potency is similar to glutamate-induced nociception
and c-Fos expression. These results are consistent to our
previous observation for both compounds on blockade of
glutamate- and NMDA-induced increases in [Ca2+]i or
neurotoxicity in cerebellar granule cells [10,11]. In con-
trast, the antinociceptive potency of magnolol is more
specific than honokiol on CHPG-induced thermal hyper-
algesia. Therefore, our data further indicate that honokiol
and magnolol may have the differential analgesic actions
on NMDA and mGlu5 receptors. However, their influence
on the activity of other subtypes of GluR is still unknown
and required further study.
During an inflammatory event, nociception generation is
a consequence of a complex interaction between a
number of inflammatory mediators, including prostag-
landins (PG), in inflamed tissues and the spinal cord.
Notably, PGE2 is the prostanoids most relevant for the
induction and maintenance of the inflammatory pain by
either increasing the primary nociceptor responses or
Effects of honokiol and magnolol on PGE2-induced nociceptive responses and thermal hyperalgesia in mice Figure 5
Effects of honokiol and magnolol on PGE2-induced nociceptive responses and thermal hyperalgesia in mice. 
Honokiol (0.5 or 1.0 μg/paw), magnolol (0.5 or 1.0 μg/paw) and vehicle were administered 20 min prior to PGE2 (0.5 μg) injec-
tion into hindpaw, and the total time spent licking the hindpaw was measured for 5 min after intraplantar injection of PGE2 (A, 
B). The paw withdrawal latency in the 47°C water was measured during 5-120 min after intraplantar injection of PGE2 (C, D). 
Each point represents the mean ± S.E.M. (n = 7-8). * indicates significantly different from vehicle group, *p < 0.05.
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Effects of honokiol and magnolol on glutamate-induced c-Fos protein expression in the spinal dorsal horn of the side ipsilateral  to the injection Figure 6
Effects of honokiol and magnolol on glutamate-induced c-Fos protein expression in the spinal dorsal horn of 
the side ipsilateral to the injection. Photomicrographs illustrating the four experimental groups are represented: corn oil 
i.p.+saline i.pl. (A), corn oil i.p.+glutamate i.pl. (B), honokiol (10 mg/kg) i.p.+glutamate i.pl. (C), and magnolol (10 mg/kg) 
i.p.+glutamate i.pl. (D). Summary data of glutamate-induced c-Fos protein expression after honokiol and magnolol treatment in 
superficial (I-II) spinal cord (E). Values are means ± S.E.M. (n = 4). # indicates significantly different from corn oil-saline group, 
#P < 0.05; * indicates significantly different from corn oil-glutamate group, *P < 0.05. Statistical analysis was determined by one-
way ANOVA followed by a Student-Newman-Keuls post-hoc test. Scale bar = 100 μm.
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changing the spinal nociceptive signaling [30]. The nocic-
eptive behavior and mechanical allodynia caused by PGE2
are attributed to the activation of G-protein-coupled EP
receptors located in intrinsic spinal neurons (EP2) or pri-
mary afferent neurons (EP1, EP3, and EP3) and protein
kinase dependent mechanisms [31,32]. Prostaglandins
are also reported to enhance the release of glutamate and
substance P from peripheral afferent fiber terminals,
involving an increase in levels of cAMP and an increase in
Ca2+  and Na+  conductance [33]. Furthermore, PGE2-
induced hyperalgesia is abolished in NMDA receptor
knock-out mice [34]. The present data showed that
honokiol and magnolol not only inhibited the nocicep-
tive response and thermal hyperlgesia induced by PGE2
but also blocked these responses induced by NMDA and
glutamate. Thus, the blockade of glutamate receptors by
honokiol and magnolol could contribute to their antino-
ciception on PGE2-induced pain responses. However, the
antinociceptive principles for interfering at the EP recep-
tors or the following signaling transduction in PGE2-
induced thermal hyperalgesia can not be excluded. Fur-
ther study is required to figure out the analgesic mecha-
nisms of honokiol and magnolol on PGE2-mediated
nociceptive and inflammatory responses.
Upon noxious stimulation, tachykinins such as substance
P and neurokinin A that are released from primary affer-
ent fibers and excite spinal cord dorsal horn neurons bind
to neurokinin receptors. It is believed that substance P
induced signaling pathway is involved in the inflamma-
tory process and in the transmission of sensory nocicep-
tive information [30,35,36]. Although the release of
substance P is facilitated by prostaglandins, substance P
and glutamate conversely increase prostaglandin release
[31]. It was observed that honokiol and magnolol signifi-
cantly reduced substance P-mediated nociceptive signals,
suggesting that the multiple antinociceptive actions of
honokiol and magnolol may be via interaction with sub-
stance P-induced nociception and pain transmission in
addition to prostaglandins and glutamate-mediated noci-
ceptive responses. However, their pharmacological mech-
anisms still require corroboration in depth.
In conclusion, the present study demonstrates that
honokiol and magnolol produce the antinociception
against glutamate-, NMDA-, CHPG-, PGE2- and substance
P-induced pain, and consistently decrease glutamate-
induced c-Fos protein expression in superficial (I-II) lam-
inae of the L4-L5 lumbar dorsal horn. It is noted that
honokiol preferentially modulates the NMDA receptor-
mediated nociception, whereas magnolol is more potent
than honokiol to inhibit mGluR5-mediated response.
Therefore, these results indicate that honokiol and mag-
nolol may possess the therapeutic potential to treat the
inflammatory pain and have the differential analgesic
mechanisms on NMDA receptor and mGluR5 activation
under nociceptive neurotransmission.
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